Primary central nervous system lymphoma
Therapeutic area
Immunology
Rare disease
Yes
- Definition
- A non-Hodgkin or Hodgkin lymphoma that arises in the brain or spinal cord as a primary lesion. There is no evidence of lymphoma outside the central nervous system at the time of diagnosis.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Primary central nervous system lymphoma
- Therapeutic area
- Immunology
- primary central nervous system lymphoma
- CNS lymphoma
- PCNSL
- central nervous system lymphoma
- lymphoma of central nervous system
- malignant lymphomas of CNS
- malignant lymphomas of the CNS
- microglioma
- primary CNS lymphoma
- primary brain lymphoma
- primary central nervous system lymphoma
- primary lymphoma, CNS
- Disease mechanisms
- Acquired
- Severity
- Severe
- Hematology
- Immunology
- Neurology
- Oncology
- MONDO ID
- MONDO:0002571
- Parent condition
- MONDO:0000621
Related records
Broader conditions (33)
- B-cell neoplasm
- Cancer
- Cancer or benign tumor
- Central nervous system cancer
- Central nervous system disorder
- Central nervous system hematopoietic neoplasm
- Central nervous system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Epstein-Barr virus-associated lymphoproliferative disorder
- Epstein-Barr virus-related tumor
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system cancer
- Immune system disorder
- Leukocyte disorder
Narrower conditions (5)
- Central nervous system anaplastic large cell lymphoma
- Central nervous system non-hodgkin lymphoma
- Cerebral lymphoma
- Diffuse large B-cell lymphoma of the central nervous system
- Spinal cord lymphoma
Trials (193)
- [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma
- [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients
- [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
- [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
- A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
- A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL
- A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
- A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
- A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators:
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
- A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL
- a Phase II Study in Primary Central Nervous System Lymphoma
- A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients
- A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
- A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
- A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma
- A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma
- A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
- A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
Drugs in development (25)
- Acalabrutinib Phase 2
- Bimiralisib Phase 2
- Camrelizumab Phase 2
- Cytarabine Phase 2
- Dexamethasone Phase 1
- Filgrastim Phase 2
- Ibrutinib Phase 2
- Idarubicin Phase 2
- Lenalidomide Phase 2
- Lisocabtagene maraleucel Phase 2
- Loncastuximab Phase 1
- Methotrexate Phase 3
- Nivolumab Phase 2
- Obinutuzumab Phase 2
- Orelabrutinib Phase 3
- Pembrolizumab Phase 2
- Pemetrexed Phase 2
- Penpulimab Phase 2
- Rituximab Phase 3
- Temozolomide Phase 3